Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall,...Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall, but also seems to participate in the atheromatic process. The correlation between LDL and CRP could form valuable guidelines for the initiation of a treatment with statins for individuals with an increased risk of ischemic incidents. Objectives: The aim of the study was to investigate a pos-sible correlation between LDL and CRP in an important number of apparently healthy indi-viduals. Methods: The study material consisted of the test results of 260 male and 484 female adults with normal LDL levels who were clini-cally healthy. The correlation between the LDL and the CRP values of this group was investi-gated in this group and CRP was compared with the respective values of a group of 60 male and 204 female adults with elevated LDL levels. Re-sults: It was ascertained that there is not a sta-tistically important correlation between LDL and CRP values in all groups (men, women, total) of the population with normal LDL levels. Addi-tionally, the CRP mean values were not statisti-cally different between the individuals with normal and raised LDL. Conclusion: A number of causes are incriminated for the results. More studies are definitely needed for the confirma-tion of the results, particularly if the findings could lead to the formation of guidelines for the application of a treatment in people with normal LDL levels but increased CRP levels.展开更多
Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholester...Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p <0.001 and 112.7 ± 34.9 mg/dL to 77.2± 29.2 mg/dL, p < 0.001 respectively, and sdLDL-C/lbLDL-C ratio and apo B also decreased significantly, from 0.36 ± 0.02 to 0.32 ± 0.02, p < 0.005 and 134.2 ± 4.3 to 93.6 ± 3.5 mg/dl, p < 0.001, respectively. In diabetic subjects there was significant correlation between percent reductions in the plasma triglyceride and sdLDL-C/ lbLDL-C ratio (r = 0.58, p < 0.005), but not between the percentage decrease in plasma triglyceride and sdLDL-C. Conclusions: Treatment with rosuvastatin is associated with significant reduction in sdLDL, lbLDL and sdLDL/lbLDL ratio.展开更多
目的探讨多系统萎缩(multiple system atrophy,MSA)患者直立性低血压的相关影响因素。方法回顾性选取2024年1月至2025年3月解放军总医院第三医学中心神经内科收治的老年MSA伴直立性低血压患者40例(MSA组),老年非直立性低血压健康体检者4...目的探讨多系统萎缩(multiple system atrophy,MSA)患者直立性低血压的相关影响因素。方法回顾性选取2024年1月至2025年3月解放军总医院第三医学中心神经内科收治的老年MSA伴直立性低血压患者40例(MSA组),老年非直立性低血压健康体检者46例(对照组),比较两组一般临床资料及相关指标,分析MSA患者直立性低血压发生的相关血液因子。结果MSA组维生素D、低密度脂蛋白胆固醇、尿酸水平明显低于对照组,差异有统计学意义(P<0.05,P<0.01)。多因素logistic回归分析显示,维生素D、低密度脂蛋白胆固醇、尿酸水平是MSA伴直立性低血压患者发生的危险因素(OR=0.677,95%CI:0.530~0.864,P<0.01;OR=0.057,95%CI:0.007~0.434,P<0.01;OR=0.972,95%CI:0.954~0.992,P<0.01)。ROC曲线分析显示,维生素D、低密度脂蛋白胆固醇、尿酸水平预测MSA伴直立性低血压发生的最佳截断值分别为21.850μg/L、2.895 mmol/L、274.500μmol/L,敏感性分别为0.848、0.630、0.783,特异性分别为0.792、0.750、0.667。曲线下面积分别为0.862、0.683、0.748。结论监测维生素D、低密度脂蛋白胆固醇、尿酸可能有助于MSA伴直立性低血压的风险评估和管理。展开更多
文摘Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall, but also seems to participate in the atheromatic process. The correlation between LDL and CRP could form valuable guidelines for the initiation of a treatment with statins for individuals with an increased risk of ischemic incidents. Objectives: The aim of the study was to investigate a pos-sible correlation between LDL and CRP in an important number of apparently healthy indi-viduals. Methods: The study material consisted of the test results of 260 male and 484 female adults with normal LDL levels who were clini-cally healthy. The correlation between the LDL and the CRP values of this group was investi-gated in this group and CRP was compared with the respective values of a group of 60 male and 204 female adults with elevated LDL levels. Re-sults: It was ascertained that there is not a sta-tistically important correlation between LDL and CRP values in all groups (men, women, total) of the population with normal LDL levels. Addi-tionally, the CRP mean values were not statisti-cally different between the individuals with normal and raised LDL. Conclusion: A number of causes are incriminated for the results. More studies are definitely needed for the confirma-tion of the results, particularly if the findings could lead to the formation of guidelines for the application of a treatment in people with normal LDL levels but increased CRP levels.
文摘Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p <0.001 and 112.7 ± 34.9 mg/dL to 77.2± 29.2 mg/dL, p < 0.001 respectively, and sdLDL-C/lbLDL-C ratio and apo B also decreased significantly, from 0.36 ± 0.02 to 0.32 ± 0.02, p < 0.005 and 134.2 ± 4.3 to 93.6 ± 3.5 mg/dl, p < 0.001, respectively. In diabetic subjects there was significant correlation between percent reductions in the plasma triglyceride and sdLDL-C/ lbLDL-C ratio (r = 0.58, p < 0.005), but not between the percentage decrease in plasma triglyceride and sdLDL-C. Conclusions: Treatment with rosuvastatin is associated with significant reduction in sdLDL, lbLDL and sdLDL/lbLDL ratio.
文摘目的探讨多系统萎缩(multiple system atrophy,MSA)患者直立性低血压的相关影响因素。方法回顾性选取2024年1月至2025年3月解放军总医院第三医学中心神经内科收治的老年MSA伴直立性低血压患者40例(MSA组),老年非直立性低血压健康体检者46例(对照组),比较两组一般临床资料及相关指标,分析MSA患者直立性低血压发生的相关血液因子。结果MSA组维生素D、低密度脂蛋白胆固醇、尿酸水平明显低于对照组,差异有统计学意义(P<0.05,P<0.01)。多因素logistic回归分析显示,维生素D、低密度脂蛋白胆固醇、尿酸水平是MSA伴直立性低血压患者发生的危险因素(OR=0.677,95%CI:0.530~0.864,P<0.01;OR=0.057,95%CI:0.007~0.434,P<0.01;OR=0.972,95%CI:0.954~0.992,P<0.01)。ROC曲线分析显示,维生素D、低密度脂蛋白胆固醇、尿酸水平预测MSA伴直立性低血压发生的最佳截断值分别为21.850μg/L、2.895 mmol/L、274.500μmol/L,敏感性分别为0.848、0.630、0.783,特异性分别为0.792、0.750、0.667。曲线下面积分别为0.862、0.683、0.748。结论监测维生素D、低密度脂蛋白胆固醇、尿酸可能有助于MSA伴直立性低血压的风险评估和管理。
